ONCOS‐102 effectively stimulated antitumor immunity, resulting in increased CD8+ T‐cell infiltration and detection of a systemic tumor‐specific CD8+ T‐cell response to MAGE‐A3/A1 and N‐ESO‐1 antigens compared with baseline, which correlated with improved survival [90]. The gene discussed is CD8A; the disease is neoplasm.